SLU-PP-332 is an experimental small-molecule agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. It is often described as an “exercise mimetic” because it activates metabolic programs normally stimulated by aerobic exercise. However, as of 2026, the evidence remains preclinical—primarily cell and mouse studies—with no established human dose, clinical efficacy, or human safety profile.
1. Effectiveness
| Potential effect | Evidence | Assessment |
| Increased exercise endurance | Increased endurance in mice | Promising preclinical evidence |
| Mitochondrial activity | Increased mitochondrial respiration in muscle cells | Strong mechanistic evidence |
| Fatty-acid oxidation | Increased in mouse skeletal muscle and metabolic models | Promising |
| Oxidative muscle fibers | Increased type IIa oxidative fibers in mice | Promising |
| Energy expenditure | Increased resting energy expenditure in obese mice | Promising |
| Fat-mass reduction | Reduced fat accumulation in mouse models | Promising but unproven in humans |
| Insulin sensitivity/glucose metabolism | Improved glucose tolerance and insulin sensitivity in mice | Preclinical only |
| Treatment of obesity/metabolic syndrome | Beneficial effects in diet-induced obese and ob/ob mice | Experimental |
The original studies found that SLU-PP-332 increased mitochondrial function and cellular respiration and promoted a more oxidative muscle phenotype. In mice, these changes translated into improved exercise endurance.
In subsequent mouse studies, SLU-PP-332 increased energy expenditure and fatty-acid oxidation, reduced fat accumulation, and improved insulin sensitivity.
2. How effective is it likely to be in humans?
This is currently unknown. The major limitation is the absence of human clinical evidence. A 2026 review specifically concludes that clinical trials are still needed to establish efficacy and safety in humans.
Therefore, claims that SLU-PP-332 increases human muscle mass, burns fat, improves athletic performance, reverses aging, or treats diabetes should not be presented as established clinical effects.
There is also an important pharmacological limitation: SLU-PP-332 has poor oral bioavailability and metabolic-stability limitations, which is one reason newer ERR agonists have been developed.
3. Side effects and toxicity
What is known
There is not enough human safety information to provide a reliable list of clinical side effects.
Animal and cell studies have not revealed obvious acute toxicity at the experimental exposures studied, and some reviews describe no evident toxicity in the reported animal experiments. However, this does not establish that SLU-PP-332 is safe for humans.
Potential concerns include:
- Unknown cardiovascular effects
- Unknown effects on liver and kidneys
- Unknown effects on glucose regulation
- Unknown effects from prolonged metabolic stimulation
- Unknown reproductive/developmental effects
- Unknown carcinogenicity with long-term exposure
- Unknown drug–drug interactions
- Unknown consequences of chronic ERR activation
These are important uncertainties rather than documented adverse effects.
Why long-term safety is particularly uncertain
ERRα/β/γ are nuclear receptors involved in broad regulation of mitochondrial function, fatty-acid metabolism, energy expenditure, and oxidative metabolism. Activating these pathways pharmacologically therefore affects many metabolic genes rather than producing a narrowly localized effect.
Consequently, short-term absence of obvious toxicity in mice cannot establish safety for chronic human use.
4. Special considerations
A. It is not an approved medicine
SLU-PP-332 should currently be regarded as a research compound/chemical probe, not an established treatment for obesity, diabetes, sarcopenia, or athletic performance.
There are currently no established human therapeutic dosing guidelines or validated clinical indications.
B. Do not extrapolate mouse doses to humans
Experimental mouse doses cannot simply be converted into a human dose. Differences in metabolism, absorption, receptor biology, exposure, and toxicity make such calculations unreliable.
C. Oral administration is problematic
SLU-PP-332 has been reported to have poor oral bioavailability, and its metabolic instability is an important drug-development limitation.
This is significant because products sold online may not reproduce the pharmacokinetic characteristics used in published animal experiments.
D. Athletic-sport consideration
This is particularly important for athletes. The 2026 analytical study notes that WADA prohibits exercise mimetics and metabolic modulators, and researchers have developed analytical methods capable of detecting SLU-PP-332 metabolites.
Thus, competitive athletes should treat SLU-PP-332 as a potentially prohibited substance and verify current rules with their governing anti-doping organization.
E. Research chemical quality is another concern
SLU-PP-332 sold through research-chemical channels is not equivalent to an approved pharmaceutical product. Purity, identity, concentration, contaminants, formulation, and stability may vary. This creates an additional safety uncertainty independent of the molecule’s intrinsic pharmacology.
5. Overall assessment
SLU-PP-332 is scientifically interesting but clinically unproven.
Potential advantages:
- Activates ERRα/β/γ metabolic signaling
- Enhances mitochondrial oxidative metabolism
- Promotes oxidative muscle-fiber characteristics
- Improves endurance in mice
- Increases fatty-acid oxidation and energy expenditure
- Improves insulin sensitivity and reduces adiposity in mouse metabolic models
Major disadvantages:
- No demonstrated human clinical efficacy
- No established human dose
- No human pharmacokinetic database
- No adequate human safety database
- Long-term toxicity is unknown
- Poor oral bioavailability/metabolic stability
- Potential anti-doping implications
Bottom line: SLU-PP-332 is a promising experimental exercise-mimetic and metabolic research compound, not a clinically validated supplement or medication. The strongest evidence currently supports its effects in cells and mice, while its effectiveness and safety in humans remain unresolved.